Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: In vitro and pharmacokinetics studies

Bhatta, Rabi Sankar; Chandasana, Hardik; Chhonker, Yashpal S.; Rathi, Chetan; Kumar, Devendra; Mitra, Kalyan; Shukla, Praveen Kumar

doi:10.1016/j.ijpharm.2012.04.060

Cited by 193 publications

(132 citation statements)

References 33 publications

Supporting

Mentioning

121

Contrasting

Order By: Relevance

“…The lecithin used is composed of 75% of phosphatidylcholine, which is composed by phospholipids that resemble the cellular membranes. The use of this emulsifier is reported as safe and biocompatible for several purposes, such as skin products (Fiume, 2001) and also for ophthalmic/ocular drug delivery (Bhatta et al, 2012). Their use in the development of LN dispersions is essential to decrease the interfacial tension between the oil phase and the internal and external aqueous phase, and also to facilitate the emulsification of the lipid matrix.…”

Section: Resultsmentioning

confidence: 99%

Design of cationic lipid nanoparticles for ocular delivery: Development, characterization and cytotoxicity

Fangueiro

Andreani

Egea

et al. 2014

International Journal of Pharmaceutics

130

View full text Add to dashboard Cite

a b s t r a c tIn the present study we have developed lipid nanoparticle (LN) dispersions based on a multiple emulsion technique for encapsulation of hydrophilic drugs or/and proteins by a full factorial design. In order to increase ocular retention time and mucoadhesion by electrostatic attraction, a cationic lipid, namely cetyltrimethylammonium bromide (CTAB), was added in the lipid matrix of the optimal LN dispersion obtained from the factorial design. There are a limited number of studies reporting the ideal concentration of cationic agents in LN for drug delivery. This paper suggests that the choice of the concentration of a cationic agent is critical when formulating a safe and stable LN. CTAB was included in the lipid matrix of LN, testing four different concentrations (0.25%, 0.5%, 0.75%, or 1.0%wt) and how composition affects LN behavior regarding physical and chemical parameters, lipid crystallization and polymorphism, and stability of dispersion during storage. In order to develop a safe and compatible system for ocular delivery, CTAB-LN dispersions were exposed to Human retinoblastoma cell line Y-79. The toxicity testing of the CTAB-LN dispersions was a fundamental tool to find the best CTAB concentration for development of these cationic LN, which was found to be 0.5 wt% of CTAB.

show abstract

Section: Resultsmentioning

confidence: 99%

Design of cationic lipid nanoparticles for ocular delivery: Development, characterization and cytotoxicity

Fangueiro

Andreani

Egea

et al. 2014

International Journal of Pharmaceutics

130

View full text Add to dashboard Cite

show abstract

“…It has widely being used in ophthalmic preparations [11]. The report by R. S. Bhatta et al showed that natamycin-loaded chitosan nanoparticles had the ability to prolong the retention time of drug on the ocular surface [12]. The efficiency of the pharmaceutical treatment of most ocular diseases is limited by short ocular residence of conventional pharmaceutical forms of drugs on the ocular mucosa due to the elimination of drug from the corneal surface by the lachrymal flow.…”

Section: Introductionmentioning

confidence: 99%

“…According to the reports [19] [20], ionic gelation is the most studied and widely used method for fabricating CS nanoparticles, in which cationic chitosan and multivalent polyanions interact to form CS nanoparticles under simple and mild conditions. Among various polyanions, TPP is the most investigated one due to its quick gelling capacity and non-toxicity property.…”

Section: Introductionmentioning

confidence: 99%

Preparation and Characterization of Novel Drug-Inserted-Montmorillonite Chitosan Carriers for Ocular Drug Delivery

Hou¹,

Gui²,

Hu³

et al. 2015

ANP

View full text Add to dashboard Cite

The objective of the study was to investigate the potential of montmorillonite as a sustained carrier in the preparation of drug-loaded nanoparticles for prolonged ocular application. Nanoparticles were prepared by ionic gelation of chitosan with sodium tripolyphosphate (TPP). Betaxolol hydrochloride (BH) was applied as a model drug. TG, FT-IR, TEM, DLS and XRD have been employed in the characterization of drug-encapsulated chitosan-montmorillonite/TPP nanoparticles (CS-MMT/TPP NPs). TEM images showed that the particles were spherical in shape and had a rough surface. The size range of the nanoparticles was between 338 and 585 nm with positive zeta potential values from 24 mV to 36 mV and encapsulation efficiency values ranging from 12.27% to 50.92%. In vitro sustained drug release was observed with the BH-loaded nanoparticles in artificial tears (pH 7.4). The results of FT-IR, TG and XRD showed that the drug was coated with CS-MMT/TPP NPs. In the mucoadhesion studies, an interaction was found between drug-loaded CS-MMT/TPP NPs and mucin, which could enhance precorneal residence time and hence facilitate an effective sustained release. The optimized formulation was determined to be non-irritant and tolerable by modified Draize test. Therefore, the BH-loading CS-MMT/TPP NPs developed are a promising carrier for controlled drug delivery to the eye.

show abstract

“…61,82 Natamycin, an antifungal agent produced by the bacterium Streptomyces natalensis, is commercially available for the treatment of corneal fungal infections. Bhatta et al 83 used lecithin mucosal adhesive nanoparticles to deliver natamycin and compared it to the commercially available natamycin ophthalmic suspension (USP Natamet). The nanoparticle increased the bioavailability of natamycin by 1.47-fold and decreased clearance by 7.4-fold.…”

mentioning

confidence: 99%

“…The nanoparticle increased the bioavailability of natamycin by 1.47-fold and decreased clearance by 7.4-fold. 83 Icaritin, a flavanol (a glycoside derivative of kaempferol) used to prevent osteoporosis, was incorporated into a nanocrystal. The incorporation caused the AUC value of icaritin to double.…”

mentioning

confidence: 99%

Natural product-based nanomedicine: recent advances and issues

Watkins¹,

Wu²,

Zhang³

et al. 2015

IJN

163

View full text Add to dashboard Cite

Natural products have been used in medicine for many years. Many top-selling pharmaceuticals are natural compounds or their derivatives. These plant- or microorganism-derived compounds have shown potential as therapeutic agents against cancer, microbial infection, inflammation, and other disease conditions. However, their success in clinical trials has been less impressive, partly due to the compounds’ low bioavailability. The incorporation of nanoparticles into a delivery system for natural products would be a major advance in the efforts to increase their therapeutic effects. Recently, advances have been made showing that nanoparticles can significantly increase the bioavailability of natural products both in vitro and in vivo. Nanotechnology has demonstrated its capability to manipulate particles in order to target specific areas of the body and control the release of drugs. Although there are many benefits to applying nanotechnology for better delivery of natural products, it is not without issues. Drug targeting remains a challenge and potential nanoparticle toxicity needs to be further investigated, especially if these systems are to be used to treat chronic human diseases. This review aims to summarize recent progress in several key areas relevant to natural products in nanoparticle delivery systems for biomedical applications.

show abstract

Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: In vitro and pharmacokinetics studies

Cited by 193 publications

References 33 publications

Design of cationic lipid nanoparticles for ocular delivery: Development, characterization and cytotoxicity

Design of cationic lipid nanoparticles for ocular delivery: Development, characterization and cytotoxicity

Preparation and Characterization of Novel Drug-Inserted-Montmorillonite Chitosan Carriers for Ocular Drug Delivery

Natural product-based nanomedicine: recent advances and issues

Contact Info

Product

Resources

About